Leonard Stein, MD; Simmy Bank, MD; Kanti Rai, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: Hyperamylasemia has been described in association with numerous solid malignant tumors (1, 2), but its association with hematologic malignancies has not been extensively studied. In a preliminary study, we found that 32% of patients with hematologic malignancies had hyperamylasemia (2). To gain more information regarding the incidence and significance of hyperamylasemia in patients with hematologic malignancies, we studied serum amylase activity in 35 patients and followed them over time (3, 4).
Forty-one consecutive patients with various hematologic malignancies were evaluated in our hematology clinic. Six patients were excluded because of concurrent illness or misdiagnosis of a hematologic
Stein L, Bank S, Rai K. Hyperamylasemia and Hematologic Malignancies. Ann Intern Med. ;116:266–267. doi: 10.7326/0003-4819-116-3-266_2
Download citation file:
Published: Ann Intern Med. 1992;116(3):266-267.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use